首页|放疗前诱导免疫治疗在不可切除Ⅲ期非小细胞肺癌中的研究进展

放疗前诱导免疫治疗在不可切除Ⅲ期非小细胞肺癌中的研究进展

扫码查看
肺癌是全世界癌症相关死亡的主要原因,其中以非小细胞肺癌(non-small cell lung cancer,NSCLC)最为常见.临床中超过 1/3的NSCLC患者在初诊时已处于Ⅲ期,且其中大部分不可切除.放化疗(chemoradiotherapy,CRT)为不可切除Ⅲ期NSCLC的标准治疗方案,然而疗效较差.随着免疫检查点抑制剂的出现,CRT后的巩固免疫治疗使得不可切除Ⅲ期NSCLC患者的生存率较单纯CRT显著提升,但仍有部分患者未能从巩固免疫治疗中获益.目前,基于诱导免疫治疗在可切除Ⅲ期NSCLC中取得的显著效果,探索诱导免疫治疗在不可切除Ⅲ期NSCLC的研究已展开.本文就放疗前的诱导免疫治疗在不可切除Ⅲ期NSCLC的作用机制、最新临床研究进展和诱导免疫治疗周期进行综述,以期为不可切除Ⅲ期NSCLC的临床治疗提供参考依据.
Research progress of induction immunotherapy before radiotherapy in unresectable stage Ⅲ non-small cell lung cancer
Lung cancer is the leading cause of cancer-related deaths worldwide,and non-small cell lung cancer(NSCLC)is the most common type.Because more than one-third of NSCLC patients are diagnosed at stage Ⅲ,most of these tumors are unresectable.Chemoradiother-apy(CRT)is the standard treatment for unresectable stage Ⅲ NSCLC;however,its curative efficacy is poor.Compared with simple CRT,the survival rate of patients with unresectable stage Ⅲ NSCLC following consolidated immunotherapy after CRT has significantly improved ow-ing to the emergence of immune checkpoint inhibitors.However,a subset of patients do not benefit from consolidated immunotherapy.Based on the effectiveness of induction immunotherapy in resectable stage Ⅲ NSCLC,studies have been conducted to extend its application in unresectable stage Ⅲ NSCLC.This article reviews the mechanism of action,recent advancements in clinical research,and cycle of induc-tion immunotherapy before radiotherapy in unresectable stage Ⅲ NSCLC to provide a reference for clinical treatment of unresectable stageⅢ NSCLC.

induction immunotherapynon-small cell lung cancer(NSCLC)research progress

曾丽、张洪攀、马代远

展开 >

川北医学院,川北医学院附属医院肿瘤科(四川省南充市 637000)

诱导免疫治疗 非小细胞肺癌 研究进展

四川省自然科学基金川北医学院附属医院项目华通国康医学研究专项

2023NSFSC07302022JB0052023HT072

2024

中国肿瘤临床
中国抗癌协会

中国肿瘤临床

CSTPCD北大核心
影响因子:1.32
ISSN:1000-8179
年,卷(期):2024.51(5)
  • 39